Ignite Creation Date:
2024-05-05 @ 10:44 PM
Last Modification Date:
2024-10-26 @ 10:23 AM
Study NCT ID:
NCT01176357
Status:
UNKNOWN
Last Update Posted:
2010-08-06
First Post:
2009-02-06
Brief Title:
Adiponectin and Inflammatory Mediators in Mediastinal Adipose Tissues
Sponsor:
Far Eastern Memorial Hospital
Organization:
Far Eastern Memorial Hospital
Study Overview
Official Title:
Adiponectin and Inflammatory Mediators in Mediastinal Adipose Tissues Between Patients With Coronary Artery Diseases and With Valvular Diseases
Status:
UNKNOWN
Status Verified Date:
2010-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Coronary artery disease CAD the most common type of heart disease is caused by hardening of the arteries or atherosclerosis that is an inflammatory process in which immune mechanisms interact with metabolic risk factors to initiate propagate and activate lesions in the arterial trees Epidemiological studies have found that increased cardiovascular risks are associated with increased levels of inflammatory cytokines eg interleukin-6 IL-6 and tumor necrosis factor-alphaTNF-alpha or their hepatic product C-reactive protein CRP Higher expression of interleukin-IbetaIL-1betaIL-6 monocyte chemotactic protein-1 MCP-1 and TNF-alpha were observed in epicardial adipose tissues in patients with CAD These findings suggested that the pericoronary tissues could be a source of inflammatory mediators or act as paracrine that lead to vascular inflammation on CAD pathogenesis However adiponectin a kind of adipocytokine produced and secreted exclusively by adipose tissue has been reported to have a variety of anti-inflammatory functions against atherosclerosis resulting in risk reduction for incidence of CAD events It remains unclear whether adiponectin and inflammatory mediators in mediastinal adipose tissue contribute to CAD We therefore aim to analyze the expression of adiponectin and inflammatory mediators in mediastinal adipose tissue between patients with CAD and with valve diseases and to correlate these parameters with clinical atherosclerotic risks medications statins or antiplatelet and blood sugar
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| FEMH-96-D-003 | None | None | None |